Doheny Asset Management /Ca Cue Biopharma, Inc. Transaction History

Doheny Asset Management /Ca

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$1.24 - $2.18 $15,698 - $27,598	12,660 New	12,660 $15,000
Q2 2021 Aug 10, 2021	SELL	$10.9 - $14.53 $138,975 - $185,257	-12,750 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$11.2 - $16.09 $6,720 - $9,654	600 Added 4.94%	12,750 $156,000
Q4 2020 Feb 26, 2021	SELL	$11.12 - $16.4 $111 - $164	-10 Reduced 0.08%	12,150 $152,000
Q3 2020 Nov 12, 2020	SELL	$15.05 - $23.54 $32,207 - $50,375	-2,140 Reduced 14.97%	12,160 $193,000
Q3 2020 Nov 12, 2020	BUY	$15.05 - $23.54 $24,682 - $38,605	1,640 Added 12.95%	14,300 $215,000
Q2 2020 Aug 18, 2020	BUY	$12.7 - $30.73 $6,350 - $15,365	500 Added 4.11%	12,660 $310,000
Q4 2019 Feb 11, 2020	BUY	$7.06 - $17.47 $85,849 - $212,435	12,160 New	12,160 $193,000

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Doheny Asset Management /Ca, based on Form 13F filings with the SEC.

Stay updated on Doheny Asset Management /Ca with notifications on news.